Conference Day Two
Thursday, April 3
8:00 am Check-In & Coffee Networking
8:55 am Chair’s Opening Remarks
Pioneering TCR Applications Beyond Oncology to Expand Treatment Potential
9:00 am Expanding TCR Therapy Success by Pursuing Autoimmune Treatments
Synopsis
• Taking learnings in TCR efficacy and safety from oncology and applying to optimize
• Evaluating your approach characteristics to determine the most suitable target indication
• Balancing durability and safety in non-oncology patient populations
9:30 am Harnessing TCR Bispecifics to Tackle Autoimmune Diseases
Synopsis
• Adapting the ImmTAX platform to address autoimmune diseases
• First clinical programme for the treatment of Type I diabetes
Unlocking the Next-Generation of TCR-Based Therapies
10:00 am Pioneering Artificial Intelligence & Machine Learning to Turbocharge TCR Therapy Development
Synopsis
• Developing AI to rapidly screen TCR molecules to predict target binding
• Accelerating screening of TCR libraries to identify effective TCR molecules with minimal off-target effects
• Utilizing AI to influence the design for optimal synthetic TCR molecules
10:30 am Morning Refreshment Break & Networking
Improving Efficacy to Reinvent Durability & Persistence in the Solid Tumor Microenvironment
11:30 am Panel Discussion: A Commercial TCR-T & TCR Bispecific – What’s Next?
Synopsis
• Discussing engineering methods to alter T-cell or bispecific properties to increase trafficking to tumor sites and enable prolonged killing
• Inhibiting immune suppression pathways to improve cell survival
• Considering implications of multi-engineering on cell viability and patient safety to mitigate adverse effects
12:30 pm Using a Novel TGF-beta Switch to Prevent Exhaustion of T-Cells in the Solid TME
Synopsis
• Introduction of a novel TGF-beta Switch Receptor: explaining how the novel switch modulates TGF-beta signaling to enhance T-cell functionality within the hostile solid tumor microenvironment (TME)
• Preventing T-cell exhaustion: demonstrating how this approach effectively prevents T-cell exhaustion, enabling repeated killing
• Implications for advanced Immunotherapies: discussing the integration of this technology into the toolbox of technologies of Captain T Cell to develop more effective treatments for solid tumors
1:00 pm Lunch Break & Networking
2:00 pm Integrating a Co-Stimulatory CD8 Co-Receptor & a Tailored Switch Receptor to Boost Persistence & Anti-Tumor Activity
Synopsis
• Identifying inhibitory factors in the tumor microenvironment by large-scale tumor screening and translating these into activating signals through switch receptors
• Leveraging inhibitory switch receptors to boost engraftment during TCR-T cell trafficking
• Equipping cells with a costimulatory CD8 co-receptor to overcome lack of co-stimulatory signaling in the tumor
Transforming Clinical Strategy to Efficiently Progress the Next Wave of Therapies
2:30 pm RoundTable: Reflecting on Current Clinical Strategy to Enable Smooth Trial Recruitment & Progression
Synopsis
• Evaluating best practice to select a target indication based on therapeutic approach
• Discussing challenges in patient screening and engagement to facilitate recruitment in early- and late-stage trials
• Sharing regulatory experiences to distinguish a clear path into and through the clinic
• Discussing manufacturability and scalability to cater to the growing patient population
3:30 pm Strategies for Clinical Dose Selection of CDR404: a MAGE-A4/HLA-A2 Antibody-Based T-Cell Engager
Synopsis
• Using Quantitative Systems Pharmacology (QSP) modeling for dose escalation and FIH study design for CDR404
• We discuss the key preclinical pharmacological data used for generation of a QSP model for CDR404
• Forward-looking perspectives and next generation antibody-based TCEs targeting peptide-HLA on cancer cells